Translating Cutting-Edge Science into Transformative Therapies
An Oncology Preclinical Venture Studio
Significant Market Opportunity
Unmet Clinical Needs
$200B+ global oncology market with 20M+ new cancer cases annually. 5-year survival rates below 50% for many cancers, with 30-50% treatment resistance and 200+ rare cancers lacking therapeutic options.
Untapped Asset Pipeline
80% of promising academic oncology discoveries never reach clinical trials. 300+ shelved pharmaceutical candidates with validated targets. 75+ high-potential assets identified for immediate development.
Optimized Development
Our AI platforms predict efficacy with 85% accuracy, cutting costs by $2-3M per asset and reducing time to clinical proof-of-concept by 30%. This increases asset value 5-8x before Series A.
Venture Studio Approach
Our model reduces early development costs by 40% and accelerates timelines by 18 months. We achieve 3x higher successful IND filing rates through specialized expertise and shared resources.
Our Growth Strategy
Asset Identification
Targeting 15-20 high-potential oncology assets annually through academic partnerships and pharma pipeline mining
Parallel Development
Advancing 5-7 assets simultaneously through shared resources and optimized preclinical workflows
Value Inflection
Creating 5-8x valuation growth via clinical proof-of-concept acceleration and strategic Series A positioning
Our Growth Strategy
1
Targeted Asset Acquisition
Rigorous selection of preclinical oncology assets validated through comprehensive pharmaceutical industry demand assessment and quantitative market valuation analysis
2
Accelerated Value Enhancement
Implementing proprietary optimization protocols and streamlined development pathways to rapidly increase asset valuation by 5-8x prior to Series A fundraising
3
Strategic Industry Alliances
Cultivating high-value partnerships with pharmaceutical leaders and innovative biotechnology ventures to leverage specialized expertise and create defined exit pathways
Our Investment Strategy
Exit Strategy
Build to IND/Phase 1 for Series A/B or acquisition
Value Creation
Rigorous diligence, internal lab work, experienced team
Sourcing
Premier academic institutions and big pharma shelved assets
Focus
Oncology only, modality agnostic approach
Our Expert Team
CEO
Serial entrepreneur with biotech leadership and proven fundraising track record.
CSO
Deep scientific expertise in oncology and track record of bringing assets to clinic.
COO
Operational excellence in company building, finance, legal, and alliance management.
Organoid Specialist
Key contractor with expertise in organoid models and bioinformatics with ownership stake.
Our Sourcing Edge
University Network
Established relationships with tech transfer offices and key opinion leaders at Ivy League institutions.
Direct access to cutting-edge research
Early visibility on promising technologies
Pharma Relationships
Strategic approach to unlock "shelved" assets from Pfizer and other major pharma companies.
BD connections across industry
Clear criteria for asset selection
Timeline
First asset in-licensed within 6 months of funding.
Target: 5 assets within first 24 months.
Our Operating Process
Discovery & Diligence
Scientific rigor, market analysis, IP strength evaluation